Since 2016, 28 life science related teams have been supported.
The teams below are currently in the ProHealth programme
ANISON develops natural compounds and small molecules for targeted treatment of HPV associated warts and cancers respectively. The team has formulated a plant-based extract as a cream/ointment to be effective in treating all kind of warts including common, plantar and genital warts. Warts are caused by HPV and the active component in the extract has been shown to be specifically effective against HPV thus targeting the underlying cause. The project is in the development phase and a start-up is planned to be established in 2020.
AVECIN-Biopharma Ltd is a cosmeceutical company focusing on development of exosome cell-free technology to stimulate and regenerate natural tissue restoration, intended to be used in repair of damaged or lost tissue as well as skin care and hair restore applications.
ENDOMET is a machine learning based diagnostic tool that provide risk assessment of endometriosis disease among women with abdominal pain symptoms. The tool supports decision making by the physicians by combining both clinical features and biomarker data. It also has a platform for self-evaluation and can be used to predict disease recurrence by the physicians. A start-up is planned to be established in the end of 2019.
Midifi Oy starts its first business concept thru Estonian and Finnish pharmacies. This service assists the patent in obtaining prescription drugs and / or prescription drugs at the desired time and location.
Midify Oy is developing a completely personal approach to deliver healthcare services to patients everywhere at every time all over Europe. In six words “it’s a fingertip medicine everywhere at every time”.
Capsamedix Oy develops devices for long-term oral drug delivery to replace pills, injections, and implants in applications, where medication may cause adverse effects or patients have difficulties in remembering to take medication. The technology allows administering drugs locally for oral diseases and through oral mucosa into the systemic circulation for systemic and localized diseases.
Finnadvance Oy is developing disease-on-chip for drug discovery and for research. The chips mimic functions of a human organ and allow for more precise and expedient drug discovery. This lowers costs by reducing the need for animal studies. The chips are used to find potential drug candidates for rare diseases and to study efficacy and response. This work will eventually lead to the development of real personalized medicines.